Lannett Company Inc.: Drug Recall

Recall #D-0096-2026 · 10/10/2025

Class II: Risk

Recall Details

Recall Number: D-0096-2026
Classification: Class II
Product Type: Drug
Recalling Firm: Lannett Company Inc.
Status: Ongoing
Date Initiated: 10/10/2025
Location: Seymour, IN, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 46,848 90-count bottles

Reason for Recall

Failed Dissolution Specifications

Product Description

Niacin Extended-release Tablets, USP, 1,000 mg, Rx Only, 90 Tablets per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC: 62175-322-46

Distribution Pattern

Nationwide in the USA

Other Recalls by Lannett Company Inc.

Class II: Risk 08/19/2025

Presence of Foreign Tablet/Capsule: Two (2) bottles labeled as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 10mg, 100ct, contained one (1) tablet of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 5 mg.
Class II: Risk 08/11/2025

Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg.
Class II: Risk 10/25/2024

Failed Content Uniformity Specifications: Product failed to meet the action limits for stratified content uniformity.
Class III: Low Risk 11/09/2022

Failed Impurity/Degradation Specifications
Class III: Low Risk 11/09/2022

Failed Impurity/Degradation Specifications

View all recalls by Lannett Company Inc. →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.